Article thumbnail

Lacrimal gland uptake on F-18 florbetapir amyloid positron emission tomography scan

By MD Malak Itani, MD Burcak Yilmaz Gunes, MD Gensuke Akaike and MD Fatemeh Behnia


In 2012, the Food and Drug Administration (FDA) approved the use of F-18 florbetapir to estimate β-amyloid neuritic plaque density when indicated. A normal scan will show increased radiotracer uptake in the white matter. Mild uptake in salivary glands, skin, muscles, and bones is considered normal. Being a new and infrequently performed study, familiarity with normal biodistribution and variants is important. We hereby present 2 cases with F-18 florbetapir uptake in lacrimal glands. Patients had no symptoms or known systemic conditions to explain this uptake. We speculate that lacrimal gland uptake of F-18 florbetapir could represent a normal variant

Topics: F-18 florbetapir, Amyloid, PET/CT, Lacrimal gland, Normal variation, Medical physics. Medical radiology. Nuclear medicine, R895-920
Publisher: Elsevier
Year: 2018
DOI identifier: 10.1016/j.radcr.2017.10.029
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.